Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8 <sup>+</sup> T cell responses

Anthony E. Zamora(St. Jude Children's Research Hospital), Jeremy Chase Crawford(St. Jude Children's Research Hospital), E. Kaitlynn Allen(St. Jude Children's Research Hospital), Xi-zhi J. Guo(St. Jude Children's Research Hospital), Jesse Bakke(St. Jude Children's Research Hospital), Robert Carter(St. Jude Children's Research Hospital), Hossam A. Abdelsamed(St. Jude Children's Research Hospital), Ardiana Moustaki(St. Jude Children's Research Hospital), Yongjin Li(St. Jude Children's Research Hospital), Ti‐Cheng Chang(St. Jude Children's Research Hospital), Walid Awad(St. Jude Children's Research Hospital), Mari Dallas(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), James R. Downing(St. Jude Children's Research Hospital), Terrence L. Geiger(St. Jude Children's Research Hospital), Taosheng Chen(St. Jude Children's Research Hospital), Douglas R. Green(St. Jude Children's Research Hospital), Ben Youngblood(St. Jude Children's Research Hospital), Jinghui Zhang(St. Jude Children's Research Hospital), Paul G. Thomas(St. Jude Children's Research Hospital)
Science Translational Medicine
June 26, 2019
Cited by 90Open Access
Full Text

Abstract

TILs restricted to one or two putative neoepitopes. Our results indicate that robust antitumor immune responses are induced in pediatric ALL despite their low mutation burdens and emphasize the importance of immunodominance in shaping cellular immune responses. Furthermore, these data suggest that pediatric cancers may be amenable to immunotherapies aimed at enhancing immune recognition of tumor-specific neoantigens.


Related Papers

No related papers found

Powered by citation graph analysis